AbbVie Inc. $ABBV Shares Sold by Capital Advisory Group Advisory Services LLC

Capital Advisory Group Advisory Services LLC lowered its stake in shares of AbbVie Inc. (NYSE:ABBV) by 37.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,223 shares of the company’s stock after selling 3,176 shares during the quarter. Capital Advisory Group Advisory Services LLC’s holdings in AbbVie were worth $1,210,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Brighton Jones LLC increased its position in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares during the period. Farther Finance Advisors LLC increased its position in shares of AbbVie by 14.4% in the second quarter. Farther Finance Advisors LLC now owns 39,100 shares of the company’s stock worth $7,257,000 after acquiring an additional 4,908 shares in the last quarter. Grant Private Wealth Management Inc raised its stake in shares of AbbVie by 399.7% in the 2nd quarter. Grant Private Wealth Management Inc now owns 11,894 shares of the company’s stock valued at $2,208,000 after acquiring an additional 9,514 shares during the period. Finally, Abacus FCF Advisors LLC raised its stake in shares of AbbVie by 13.4% in the 2nd quarter. Abacus FCF Advisors LLC now owns 122,668 shares of the company’s stock valued at $22,770,000 after acquiring an additional 14,536 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on ABBV. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Bank of America upped their price target on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $247.84.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

AbbVie Price Performance

ABBV opened at $214.38 on Monday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The stock has a market capitalization of $378.89 billion, a PE ratio of 162.41, a P/E/G ratio of 0.88 and a beta of 0.36. The firm’s fifty day moving average price is $226.80 and its 200 day moving average price is $216.65.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.